The manufacturer of the Evorel® range of HRT patches has written healthcare professionals advising of an imminent supply shortage.
An increase in demand for the products is cited as one of the reasons for the shortage with the entire product range affected - Evorel®, Evorel® Sequi and Evorel® Conti. It is anticipated that supplies will be restored in mid-2020.
Alternative patches are available to switch from Evorel®, but alternatives to the Sequi and Conti products are going to be more complex, perhaps involving supply of oestrogen patches and progestogen tablets or a switch to tablet versions.
Action: Clinicians should be aware of this supply interruption and be prepared to supply appropriate alternatives.
|« SMC Update - August 2019||Drug Safety Update - August 2019 »|